ArticleBiological trace element research2026
Chrysin Mitigates Chromium-Induced Nephrotoxicity Via Modulation of AMPK/SIRT1/NF-κB/p53 Signaling Cascade and PGC-1α Signaling.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardioprotective role of vincamine in cyclophosphamide-induced cardiotoxicity through modulation of AMPK/SIRT1, PI3K/Akt, and MAPK pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Protective effects of thymoquinone against hexavalent chromium-ınduced nephrotoxicity: a multiparametric evaluation of oxidative stress, ınflammation, ferroptosis- and apoptosis-related markers.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hexavalent chromium [Cr(VI)] is a hazardous heavy metal that poses serious toxicity to humans, in particular nephrotoxicity. The current work explored the potential nephroprotective impact of chrysin against Cr(VI)-induced nephrotoxicity. Chrysin significantly improved renal functions in the Cr(VI)-treated rats as indicated by decreased levels of urinary protein loss, serum creatinine and urea, and renal lipocalin-2, together with improved renal histopathological picture. Mechanistically, chrysin upregulated AMPK signaling as evidenced by a significant increase in phospho-AMPK and its downstream target SIRT1. These findings were accompanied by a significant decrease in the acetylated (active) forms of NF-κB and p53 the transcription factors that control inflammation and apoptosis. Additionally, chrysin inhibited NF-κB nuclear translocation, increased level of its cytosolic inhibitory protein IκB, and reduced levels of its responsive inflammatory molecules interleukin-6 and cyclooxygenase-2. Moreover, it modulated levels of p53-responsive apoptotic proteins BAX and Bcl2. Interestingly, chrysin boosted the master regulator of mitochondrial biogenesis PGC-1α, modulated its responsive proteins DRP1 and MFN2, increased activity of the antioxidant enzymes catalase and thioredoxin reductase, together with inhibition of lipid hydroperoxidation and DNA oxidation. Collectively, these findings highlight the mitigating activity of chrysin against Cr(VI)-induced nephrotoxicity and underscore AMPK, SIRT1, NF-κB, p53, and PGC-1α as underlying molecular targets.
Indexed as
Identifiers
40457156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.